Lifecare ASA is a Norway-based company that develops miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers. Lifecare's activities are concentrated on the development of sensor for use as a medical product, initially the sensor Sencell for continuous monitoring of glucose (blood sugar) for people with diabetes. The technology is suitable for detecting and measuring a wide range of molecules that can occur in the human body, based on variations in osmotic pressure.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-06-12	0.2900 kr	-3.33%	9,683,883
26-06-11	0.3000 kr	-9.09%	21,059,360
26-06-10	0.3300 kr	+10.74%	37,858,430
26-06-09	0.2980 kr	-6.88%	1,079,841
26-06-08	0.3200 kr	+8.47%	2,859,267

Real-time Oslo Bors

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Oslo Bors Other stock markets 10:45:00 2026-06-12 EDT			5-day change	1st Jan Change
0.2900 ^NOK	-3.33%		-3.01%	-91.10%

06-10	Lifecare Completes First Six-Month Implant Evaluation With Continued Functionality and No Adverse Biological Response	CI
05-15	Lifecare ASA, Q1 2026 Earnings Call, May 15, 2026

Market Cap	86.45M 9.11M 7.87M 7.25M 6.79M 12.72M 866M 12.92M 85.61M 33.38M 421M 34.19M 33.46M 1.46B	P/E Ratio 2026 *	-0.76x	P/E Ratio 2027 *	-1.04x
Enterprise Value	122M 12.9M 11.14M 10.27M 9.61M 18.02M 1.23B 18.29M 121M 47.28M 597M 48.43M 47.4M 2.07B	EV / Sales 2026 *	-	EV / Sales 2027 *	24.9x
Free-Float	51.56%	Yield 2026 *	-	Yield 2027 *	-

06-10	Lifecare Completes First Six-Month Implant Evaluation With Continued Functionality and No Adverse Biological Response	CI
05-15	Lifecare ASA, Q1 2026 Earnings Call, May 15, 2026
05-15	Lifecare ASA Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-15	Lifecare Q1 operating loss NOK 31.5 mln	RE
04-23	Lifecare ASA Approves Board Appointments	CI
03-26	Lifecare ASA Announces Operational Restructuring And Centralization Of Operations	CI
03-26	Lifecare ASA Announces Discontinuation of the Business Operations of Lifecare Germany GmbH	CI
03-26	Lifecare ASA to Close German Operations, Consolidate Activities Under Planned Centralization	MT
03-16	Lifecare Chief Scientific Officer to Step Down	MT
03-13	Andreas Pfützner to Step Down as Chief Scientific Officer of Lifecare ASA	CI
03-10	Lifecare receives regulatory feedback on first-in-human application	RE
03-09	Lifecare ASA Receives Regulatory Feedback on First-in-Human Application	CI
03-05	Lifecare ASA Confirms 12-Week Implant Stability Under Real-Life Conditions And Reduces Durability Risk Ahead Of First-In-Human Study	CI

06-12	Lifecare ASA: Final results following expiry of exercise period for Warrants Series 2 issued in connection with Rights Issue	PU
06-10	Lifecare ASA: Mandatory notification of trade	PU
06-10	Lifecare completes first six-month implant evaluation with continued functionality and no adverse biological response	AQ
06-01	Lifecare ASA: Commencement of the Exercise Period for Warrants Series 2 issued in connection with the Rights Issue	PU
05-19	Lifecare ASA: Mandatory notification of trade	PU

Lifecare ASA Stock

Stocks

LIFE

NO0013355859

Biotechnology & Medical Research

Valuation: Lifecare ASA

Chart: Lifecare ASA

Latest news : Lifecare ASA

Last Transcript: Lifecare ASA

Analysts' recommendations: Lifecare ASA

Press Releases: Lifecare ASA

News in other languages: Lifecare ASA

Quotes and Performance

Course Extremes

Managers and Directors: Lifecare ASA

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	-3.33%
1 week	-3.01%
Current month	-12.25%
1 month	-27.41%
3 months	-18.99%
6 months	-94.02%
Current year	-91.10%

1 week	0.27	0.42
1 month	0.27	0.42
Current year	0.27	2
1 year	0.27	23.5
3 years	0.27	82.16
5 years	0.27	82.16
10 years	0.27	117

Manager	Title	Age	Since
Joacim Holter CEO	Chief Executive Officer	50	2020-09-06
Petter Nielsen DFI	Director of Finance/CFO	-	2026-03-31
Torsten Ernst PRN	Corporate Officer/Principal	-	2024-02-29

Director	Title	Age	Since
Trine Teigland BRD	Director/Board Member	-	2020-06-25
Morten Foros Krohnstad CHM	Chairman	-	2021-05-07
Lutz Heinemann BRD	Director/Board Member	-	2020-11-19

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LIFECARE ASA	-3.33%	-3.01%	-95.62%	-98.84%	9.39M
LONZA GROUP AG	-0.35%	-0.22%	-15.03%	-12.88%	42.96B
REVOLUTION MEDICINES, INC.	+3.11%	-1.17%	+277.22%	+502.47%	31.73B
IQVIA HOLDINGS INC.	+0.22%	-2.90%	+14.25%	-12.16%	30.22B
BEONE MEDICINES AG	+1.62%	-5.52%	+0.79%	+22.42%	28.94B
CELLTRION, INC.	+4.09%	-1.98%	+11.99%	+17.37%	23.87B
MEDPACE HOLDINGS, INC.	-1.63%	+1.89%	+54.59%	+124.83%	13.57B
EUROFINS SCIENTIFIC SE	-0.40%	-1.48%	+7.48%	+7.12%	12.96B
ASCENDIS PHARMA A/S	+1.14%	-0.36%	-	-	13.39B
IONIS PHARMACEUTICALS, INC.	-0.74%	-2.47%	+102.47%	+80.26%	12.2B
Average	+0.37%	-0.60%	+39.79%	+70.07%	20.98B
Weighted average by Cap.	+1.02%	-1.08%	+55.88%	+95.95%

	2026 *	2027 *
Net sales	-	5M 527K 455K 419K 393K 736K 50.08M 747K 4.95M 1.93M 24.38M 1.98M 1.94M 84.4M
Net income	-86M -9.06M -7.83M -7.21M -6.75M -12.65M -861M -12.85M -85.16M -33.2M -419M -34.01M -33.29M -1.45B	-82M -8.64M -7.46M -6.88M -6.44M -12.06M -821M -12.25M -81.2M -31.66M -400M -32.43M -31.74M -1.38B
Net Debt	36M 3.79M 3.28M 3.02M 2.83M 5.3M 361M 5.38M 35.65M 13.9M 176M 14.24M 13.93M 608M	38M 4M 3.46M 3.19M 2.98M 5.59M 381M 5.68M 37.63M 14.67M 185M 15.03M 14.71M 641M